Jas Uppal
Keine laufenden Positionen mehr
Profil
Jas Uppal worked as Director & Head-Global Emerging Markets at Biogen, Inc., Manager-Worldwide Regulatory Affairs at PAREXEL International Corp., and Chief Regulatory & Quality Officer at Gamida Cell Ltd.
She also served as VP-Regulatory Affairs & Pharmacovigilance at Karyopharm Therapeutics, Inc. from 2015 to 2017 and as Vice President & Global Head-Regulatory Affairs at Ipsen Biopharmaceuticals, Inc. from 2017 to 2019.
Uppal holds a doctorate degree from King's College London and an undergraduate degree from Queen Mary University of London.
Ehemalige bekannte Positionen von Jas Uppal
| Unternehmen | Position | Ende |
|---|---|---|
| Ipsen Biopharmaceuticals, Inc. | Corporate Officer/Principal | 01.01.2019 |
| KARYOPHARM THERAPEUTICS INC. | General Counsel | 01.01.2017 |
| GAMIDA CELL LTD. | General Counsel | - |
| BIOGEN INC. | Direktor/Vorstandsmitglied | - |
| PAREXEL INTERNATIONAL CORPORATION | General Counsel | - |
Ausbildung von Jas Uppal
| King's College London | Doctorate Degree |
| Queen Mary University of London | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| KARYOPHARM THERAPEUTICS INC. | Health Technology |
| BIOGEN INC. | Health Technology |
| GAMIDA CELL LTD. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
PAREXEL International Corp.
 PAREXEL International Corp. Miscellaneous Commercial ServicesCommercial Services PAREXEL International Corp. provides biopharmaceutical services. It offers clinical research and logistics, medical communications, consulting, commercialization and advanced technology products and services for pharmaceutical, biotechnology and medical device industries. The company was founded in 1983 and is headquartered in Newton, MA. | Commercial Services |
| Ipsen Biopharmaceuticals, Inc. |
